Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

PURPOSE: ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). ARN-509 inhibits AR nuclear translocation and AR binding to androgen response elements and, unlike bicalutamide, does not exhibit agonist properties in the context of AR ov...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Rathkopf, Dana E., Morris, Michael J., Fox, Josef J., Danila, Daniel C., Slovin, Susan F., Hager, Jeffrey H., Rix, Peter J., Chow Maneval, Edna, Chen, Isan, Gönen, Mithat, Fleisher, Martin, Larson, Steven M., Sawyers, Charles L., Scher, Howard I.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2013
Teme:
Original Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3782148/
https://ncbi.nlm.nih.gov/pubmed/24002508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.50.1684
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki